Clover Biopharmaceuticals snaps up $230m Series C

Clover Biopharmaceuticals, a global clinical-stage biotechnology company, has secured $230 million in Series C financing.

23 February 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles